Insilico Medicine and SK Biopharmaceuticals have entered a research collaboration to discover new medicines using artificial intelligence, in a deal the companies value at up to $2.5 billion.
According to Applied Clinical Trials and News-Medical, the partnership targets neuroimmune disorders of the central nervous system — conditions where the immune system and the brain or nervous system interact to drive disease. Under the arrangement, Insilico's Pharma.AI platform will generate drug candidates, while SK Biopharmaceuticals, a South Korea-based biotech, takes them forward in development.
Insilico Medicine describes itself as a clinical-stage company that uses generative AI to discover drugs, and trades in Hong Kong under the ticker 3696.HK. The $2.5 billion figure represents the deal's potential maximum value rather than cash paid up front. Fierce Biotech characterized the agreement as "heavily backloaded," meaning most of that money is tied to future milestones — such as research, development, and commercial progress — and would only be paid if the partnership's drug candidates advance successfully.
The announcement, reported across outlets including Bioengineer.org, The Manila Times, and AIM Media House on June 22, 2026, is the latest example of a large pharmaceutical company partnering with an AI-focused biotech to speed up the slow, expensive early stages of drug discovery.
Why it matters: Big-dollar AI drug deals like this one show that established drugmakers are betting real money on machine-generated candidates — but the backloaded structure is a reminder that the headline number depends entirely on whether the science actually delivers.